Sevelda P
Abteilung für Geburtshilfe und Gynäkologie, Universitäts-Frauenklinik, Wien.
Wien Med Wochenschr. 1996;146(1-2):18-22.
Aim of primary surgery in early stage ovarian cancer (FIGO I-IIA) is a complete removal of all visible tumors and an exact staging of intraabdominal and retroperitoneal tumor spread. Debulking of tumor as radical as possible is the aim of surgery in advanced stages of disease (FIGO IIb-IV). After 2 to 3 cycles of an active polychemotherapy interventional debulking surgery is performed with the intention to remove all existing tumors in those patients with postoperative residual tumor masses > 1 cm in diameter after first surgery. Second-look surgery is performed after 6 cycles of first line polychemotherapy either to confirm a clinical complete remission pathohistologically or to debulk persisting residual tumors. Secondary tumordebulking and its influence on survival as well as the diagnostic value of second-look surgery is discussed controversially, so today second-look is confined to clinical protocols. Cytoreduction of relapsing tumor masses seems to prolong survival in those patients with a relapse free interval of more than 12 months. This seems to be an attractive therapeutic alternative. For the future one can expect more selective operation strategies on the basis of new biologic prognosticators and new developments in minimal invasive operation techniques.
早期卵巢癌(FIGO I-IIA期)初次手术的目的是完全切除所有可见肿瘤,并对腹腔内和腹膜后肿瘤扩散进行准确分期。在疾病晚期(FIGO IIb-IV期),手术的目的是尽可能彻底地切除肿瘤。在进行2至3个周期的积极多药化疗后,对初次手术后残留肿瘤直径>1 cm的患者进行介入性减瘤手术,目的是切除所有现存肿瘤。在一线多药化疗6个周期后进行二次探查手术,以病理组织学确认临床完全缓解或切除持续存在的残留肿瘤。二次肿瘤减瘤及其对生存的影响以及二次探查手术的诊断价值存在争议,因此如今二次探查手术仅限于临床方案。对于无瘤间期超过12个月的复发肿瘤患者,减少复发性肿瘤肿块似乎可延长生存期。这似乎是一种有吸引力的治疗选择。未来,基于新的生物学预后指标和微创操作技术的新发展,有望出现更具选择性的手术策略。